Background: The association of genetic single-nucleotide polymorphisms (SNPs) related to endothelial function, inflammation, and their outcomes remains poorly studied.
Objectives: To evaluate the occurrence of ischemic stroke (IS) and other vascular events, and relationships between 19 SNPs in genes associated with endothelial function and inflammation with outcomes in a population at high risk of stroke.
Design: A prospective cohort study and multi-center community-based sectional survey.
Methods: As a part of the China National Stroke Screening Survey program, the investigation was carried out in southern China from May 2015 to January 2020. Participants from 8 randomly selected. In people who were determined to be at high risk of stroke, 19 SNPs were examined. Over an average follow-up period of 4.7 years, the results of these subjects were monitored using a longitudinal method. A new IS was the primary outcome assessed, and a combination of new vascular events was the secondary outcome.
Results: In total, 2893 participants were classified as high-risk for stroke, and 2698 were monitored for 4.7 years, resulting in 192 participants (7.1%) experiencing various outcomes. Out of these, 118 individuals (4.4%) had a novel IS, 24 (0.9%) suffered a hemorrhagic stroke (HS), 53 (2.0%) developed myocardial infarction (MI), and 33 (1.2%) passed away. Significant variations have been found in the genotype distributions of rs752998, rs4845625, and rs3093662 among participants with adverse outcomes compared to those without. Generalized multifactor dimensionality reduction (GMDR) analysis identified a substantial SNP-SNP interaction involving rs932650, rs1927911, and rs4845625 ( = .004). The high-risk genotypes of these 3 SNPs were linked to an increased risk of IS (OR = 2.186, 95% CI: 1.247-5.426, < .001) and total vascular events (OR = 2.367, 95% CI: 1.433-5.798, < .001), according to multivariate logistic regression adjusted for covariates.
Conclusion: The incidence of IS and other vascular events was significantly greater among participants who were categorized as being at high risk for stroke. The interacting high-risk genotypes of rs932650, rs1927911 and rs4845625 were independently associated with an increased risk of new IS and other vascular events.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11700415 | PMC |
http://dx.doi.org/10.1177/11795735241312660 | DOI Listing |
Pharmaceutics
November 2024
Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, Nishi-tokyo, Tokyo 202-8585, Japan.
Anticoagulant therapy, particularly the use of direct oral anticoagulant agents (DOACs), is recommended for patients with nonvalvular atrial fibrillation (NVAF). This multicenter observational retrospective cohort study aimed to assess the efficacy and safety of DOACs compared to warfarin in Japanese patients aged 75 years and older with NVAF. Data from the Mie-Life Innovation Promotion Center Database were used to collect medical information on the patients.
View Article and Find Full Text PDFNutrients
December 2024
Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, 41013 Seville, Spain.
Transient ischemic attack (TIA) is a well-established risk factor for future strokes, making interventions that target recovery and vascular risk crucial. This study aimed to assess the safety and clinical effects of a polyphenol-rich extract in post-TIA patients. A randomized, triple-blind, placebo-controlled trial was conducted with participants who had a history of TIA or minor stroke and who received 1 g of Salicornia extract or placebo over 11 months.
View Article and Find Full Text PDFPharmaceuticals (Basel)
November 2024
Independent Researcher, 5345 MT Oss, The Netherlands.
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations.
View Article and Find Full Text PDFPharmaceuticals (Basel)
November 2024
Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Road, Wuhan 430030, China.
: Our purpose was to appraise the efficacy and safety of intravitreous vascular endothelial growth factor inhibitor (anti-VEGF) therapy combined with steroids for persistent diabetic macular edema. : A systematic review was conducted of the research evaluating the combination therapy of anti-VEGF and steroids for persistent diabetic macular edema compared to anti-VEGF alone. A meta-analysis was performed using a protocol registered in PROSPERO (CRD42023476333).
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Pharmacology, Chonnam National University Medical School, Hwasun 58128, Republic of Korea.
Calcium deposition in vascular smooth muscle cells (VSMCs), a form of ectopic ossification in blood vessels, can result in rigidity of the vasculature and an increase in cardiac events. Here, we report that CCAAT/enhancer-binding protein beta (C/EBPβ) potentiates calcium deposition in VSMCs and mouse aorta induced by inorganic phosphate (Pi) or vitamin D. Based on cDNA microarray and RNA sequencing data of Pi-treated rat VSMCs, C/EBPβ was found to be upregulated and thus selected for further evaluation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!